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Abstract
Human cd T cells are innate-like T cells which are able to kill a broad range of
tumour cells and thus may have potential for cancer immunotherapy. The
activating receptor natural killer group 2 member D (NKG2D) plays a key role
in regulating immune responses driven by cd T cells. Here, we explored whether
recombinant immunoligands consisting of a CD20 single-chain fragment
variable (scFv) linked to a NKG2D ligand, either MHC class I chain-related
protein A (MICA) or UL16 binding protein 2 (ULBP2), could be employed to
engage cd T cells for tumour cell killing. The two immunoligands, designated
MICA:7D8 and ULBP2:7D8, respectively, enhanced cytotoxicity of ex vivo-
expanded cd T cells against CD20-positive lymphoma cells. Both Vd1 and Vd2
cd T cells were triggered by MICA:7D8 or ULBP2:7D8. Killing of CD20-
negative tumour cells was not induced by the immunoligands, indicating their
antigen specificity. MICA:7D8 and ULBP2:7D8 acted in a dose-dependent
manner and induced cytotoxicity at nanomolar concentrations. Importantly,
chronic lymphocytic leukaemia (CLL) cells isolated from patients were sensitized
by the two immunoligands for cd T cell cytotoxicity. In a combination approach,
the immunoligands were combined with bromohydrin pyrophosphate (BrHPP),
an agonist for Vd2 cd T cells, which further enhanced the efficacy in target cell
killing. Thus, employing tumour-directed recombinant immunoligands which
engage NKG2D may represent an attractive strategy to enhance antitumour
cytotoxicity of cd T cells.
Introduction
Human cd T cells are innate-like T lymphocytes that
recognize stressed cells in the context of infection or
malignant transformation [1, 2]. In peripheral blood, cd T
cells represent 1–5% of CD3-positive lymphocytes. While
up to 90% of peripheral blood, cd T cells carry a distinct
Vc9Vd2 TCR, the majority of intra-epithelial cd T cells
express Vd1 paired with various Vc chains [3]. In contrast
to ab T cells, cd T cells are activated by non-peptide
antigens independently of antigen processing and MHC
presentation. Whereas ligands for the Vd1 TCR are not
well defined, Vc9Vd2 T cells were shown to recognize
certain sets of phosphorylated intermediates of the iso-
prenoid pathway commonly referred to as phosphoantigens
(PAg), which are presented by tumour cells in a manner
not yet fully understood with butyrophilin subfamily 3
member A1 (CD277) playing an important role [4, 5].
Recent studies indicate that human CD277 molecules,
which play key mandatory roles in the PAg-induced
activation of Vc9Vd2 T cells, do not directly present PAg
compounds to T cells. Data from Sebestyen and colleagues
support an inside-out signalling mechanism for CD277
whereby intracellular PAg accumulation is translated into
surface changes of CD277 by small GTPase RhoB resulting
in recognition of the extracellular CD277 domain by
Vc9Vd2 TCR [6].
Apart from the TCR, tumour cell recognition by cd T
cells involves germline-encoded killer activating receptors
including natural killer group 2 member D (NKG2D) [7].
NKG2D, which is also expressed by NK cells and CD8-
positive ab T cells, recognizes multiple stress-inducible
self-molecules including MHC class I chain-related protein
(MIC) A and B and unique long-16 binding proteins
(ULBP) 1–6 [8–10]. The NKG2D ligands are rarely
expressed on healthy tissues, but are frequently upregulated
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upon cellular stress such as malignant transformation [11].
Consequently, NKG2D ligands function as danger signals
enabling recognition and elimination of tumour cells by
cytotoxic lymphocytes. Interestingly, some NKG2D
ligands (i.e. MICA, ULBP3, ULBP4) were shown to be
recognized also by a number of Vd1 and Vd2 TCRs,
suggesting that these danger signals might trigger cd T
cell activation both via TCR as well as NKG2D [12–16].
Whereas it is widely appreciated that ligation of NKG2D
by corresponding ligands directly triggers NK cell
cytotoxicity and co-stimulates ab T cells, the relative
contribution of NKG2D versus the TCR for cd T cell
cytotoxicity is not precisely clear [10, 11, 17, 18]. The
observation that cd T cell cytotoxicity was induced by
NKG2D engagement also in the absence of TCR
signalling suggested that like in NK cells, NKG2D
may function as a primary activating receptor in cd T
cells [15, 19]. In addition, NKG2D signalling may enable
cd T cells to discriminate malignant from normal cells
[20].
Several important functions of cd T cells in tumour
immune surveillance have been demonstrated in murine
tumour models [21–23]. Moreover, the numbers of
circulating cd T cells were found to be increased in certain
patients with haematological malignancies including
chronic lymphocytic leukaemia (CLL), and observed dys-
functional Vc9Vd2 T cells were reported to be a negative
prognostic factor in CLL – suggesting that these T cells
contribute to the control of the disease in humans [24–26].
In clinical trials, the potential of cd T cell-based cancer
immunotherapy was investigated [1]. To this end, cd T
cells were activated ex vivo and expanded using PAg such as
2-methyl-3-butenyl-1-pyrophosphate (2M3B1-PP), bro-
mohydrin pyrophosphate (BrHPP) or aminobisphospho-
nates (n-BP), and then adoptively transferred into the
patients. In other approaches, in vivo stimulation of cd T
cells by administration of IL-2 or agonistic n-BPs such as
pamidronate, zoledronate or PAg phosphostim (IPH1101)
were evaluated [27–33]. Although these studies revealed a
clinical benefit in some patients, novel strategies further
enhancing the antitumoral activities of cd T cells are
warranted.
Increasing the surface density of NKG2D ligands on the
surface of malignant cells may provide an innovative
strategy to enhance antitumoral activities by NKG2D-
positive NK and T cells and may allow boosting cd T cell
cytotoxicity [34]. Previously, in an attempt to attract NK
cells, two recombinant immunoligands containing a CD20
single-chain fragment variable (scFv) and a NKG2D ligand
(i.e. ULBP2 or MICA) were applied to decorate lymphoma
and leukaemia cells exogenously with NKG2D ligands,
which resulted in enhanced NK cell-mediated tumour cell
killing [35, 36]. However, the abilities of such recombi-
nant immunoligands to trigger other NKG2D-positive,
cytotoxic effector cell populations apart from NK cells have
not been investigated in detail. On the basis of the role of
NKG2D ligands in the regulation of cd T cell cytotox-
icity, we hypothesized that tumour cell-directed NKG2D
ligands could be able to enhance cd T cell cytotoxicity as
well. Thus, we investigated the two recombinant CD20-
directed immunoligands for their ability to enhance
cytotoxic activities of cd T cells against B-lineage
lymphoma or leukaemia cells.
Materials and methods
Cell culture. Ramos, Raji, Daudi and CEM cells (DSMZ,
the German Resource Centre for Biological Material;
Braunschweig, Germany) were cultured in RPMI 1640
GlutaMax-I medium (Invitrogen, Life Technologies, Karl-
sruhe, Germany) supplemented with 10% foetal calf serum
(FCS; Invitrogen, Life Technologies), 100 units/ml peni-
cillin and 100 lg/ml streptomycin (Invitrogen, Life
Technologies). INA-6 myeloma cells were cultured as
described [37]. Lenti-X 293T cells (Clontech, Saint-
Germain-en-Laye, France) were cultured in Dulbecco’s
modified Eagle medium (DMEM; Invitrogen, Life Tech-
nologies) containing 10% FCS, 100 units/ml penicillin
and 100 lg/ml streptomycin, and CHO-K1 cells (DSMZ)
in chemically defined CHO medium (Invitrogen, Life
Technologies) supplemented with 50 units/ml penicillin,
50 lg/ml streptomycin and HT supplement (Invitrogen,
Life Technologies).
Preparation of cd T cells. The Department of Transfusion
Medicine in Kiel, Germany, provided leukocyte concen-
trates from healthy adult blood donors, who gave their
informed consent. Additionally, heparinized blood was
provided from healthy donors. The research was approved
by the relevant institutional review board (code number:
D405/10 und 404/14). Briefly, PBMC were isolated by
Ficoll–Hypaque gradient density centrifugation. PBMC
were cultured in RPMI 1640 containing 2 mmol/l L-
glutamine, 25 mmol/l HEPES, antibiotics and 10% FCS.
To obtain short-term activated Vc9Vd2 cd T cells, PBMC
were stimulated with 300 nmol/l of PAg BrHPP (kindly
provided by Innate Pharma, Marseille, France) and 50 U/
ml rIL-2 (Novartis, Basel, Suisse). IL-2 was added every
2 days over a period of 2–3 weeks. cd T cells with a lower
purity were subjected to magnetic separation to deplete
remaining non-cd T cells. Short-term activated Vd1 cd T
cells were generated by staining PBMC with anti-TCRVd1
mAb (Immunotech/Beckman Coulter, Krefeld, Germany)
followed by positive selection with Dynabeads (Dynal,
Thermo Fisher Scientific). Magnetically isolated Vd1 cd T
cells as well as several short-term activated Vd2 cd T cells
(Table S1) were re-stimulated with feeder cells, which
included 40 grey irradiated PBMC (1:2 ratio) and 60 grey
irradiated EBV-transformed B cell lines (1:10 ratio) as well
as 0.5 lg/ml PHA and 50 U/ml rIL-2. The purity of the
cells was determined 2–3 weeks after initial stimulation or
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re-stimulation by flow cytometry. Most cd T cell prepa-
rations had a purity >97% (Table S1).
Recombinant immunoligands. The recombinant immuno-
ligands MICA:7D8 and ULBP2:7D8, which each contain
the human CD20 scFv 7D8 and either the extracellular
part of MICA or ULBP2, were constructed as described
previously [35]. Expression vectors for control proteins
were generated by replacing the sequences encoding the
scFv 7D8 [38] by sequences coding for either the CD7 scFv
TH69, or an scFv specific for HM1.24 in the expression
vectors pSecTag2/MICA:7D8-myc-his and pSecTag2/
ULBP2:7D8-myc-his [35, 39, 40]. Correct sequences were
confirmed by Sanger sequencing. The proteins were
expressed and purified as described [35]. SDS-PAGE and
Western transfer experiments were performed according to
standard procedures using mouse antipenta-His (Qiagen,
Hilden; Germany) and secondary horseradish peroxidase-
conjugated goat anti-mouse IgG antibodies for detection
(Dianova, Hamburg, Germany). Immunoligands were
deglycosylated under denaturing reaction conditions using
Protein Deglycosylation Mix (New England BioLabs,
Frankfurt, Germany) containing the enzymes O-glycosi-
dase, PNGase F, neuraminidase, b1-4 galactosidase and b-
N-acetylglucosaminidase according to the manufacturer’s
instructions. For Western blotting, 1.5 lg of proteins were
loaded onto a gel.
Homology models. Separate homology models were calcu-
lated for the scFv 7D8 and the extracellular domains of
MICA and ULBP2 using YASARA Structure software
(YASARA Biosciences, Graz, Austria) after removal of
sequences for the corresponding secretion leaders and C-
terminal tags. The model structure for the whole fusion
proteins were then obtained by fusing the best-fitting
models for the single subunits after introducing the linker
sequences. Ribbon drawings were generated using Discov-
ery Studio 2.0 Visualizer software (Accelrys, San Diego,
CA, USA).
Flow cytometric analysis. Flow cytometry was performed
on flow cytometers FC 500 or Navios (Beckmann Coulter,
Brea, CA, USA) as described [36]. The hexa-histidine-
tagged recombinant immunoligands were detected with a
secondary Alexa Fluor 488-conjugated antipenta-His anti-
body (Qiagen). Alternatively, cell-bound immunoligands
and the endogenously expressed MICA/B and ULBP2 were
analysed with phycoerythrin (PE)-labelled antibodies
(R&D Systems, Wiesbaden, Germany). Unless otherwise
indicated, MICA:7D8 and ULBP2:7D8 were used at
15 lg/ml. Apparent CD20 binding affinities were derived
from dose–response curves. CD20 expression on primary
tumour cells was verified with a FITC-conjugated antibody
obtained from BD Biosciences (Heidelberg, Germany). cd
T cell lines were characterized with the following mAb:
CD3 (clone SK7; BD Biosciences), anti-TCRcd (clone
11F2; BD Biosciences), anti-TCRVd1 (clone TS8.2;
Thermo Fisher Scientific, Karlsruhe, Germany), anti-
TCRVd2 (clone Immu389; Beckman Coulter) and anti-
NKG2D (clone 149810; R&D Systems). Appropriate
isotype antibodies were used as controls.
Cytotoxicity assay. Cytotoxic properties of MICA:7D8
and ULBP2:7D8 were investigated in standard 51Cr-
release experiments performed in 96-well microtiter plates
as described [36]. Briefly, 1 9 106 target cells were
labelled with 100 lCi of 51Cr for 2 h. Cells were washed
three times and the cell number was adjusted to
1 9 105 cells/ml. Medium (100 ll) and immunoligands
at the indicated concentrations were added to round
bottom microtiter plates before cd T cells (50 ll) and
target cells (50 ll) were applied, resulting in a final
volume of 200 ll. After 3 h at 37 °C, assays were stopped
by centrifugation. Twenty-five microlitre of supernatant
were mixed with 125 ll scintillation solution (OptiPhase
Supermix; Perkin Elmer, Waltham, USA), incubated with
agitation for 15 min and analysed with a beta counter. 51Cr
release from triplicates was measured in counts per minute
(cpm). Percentage of cd T cell cytotoxicity was calculated
using the formula: % specific lysis = (experimental
cpm – basal cpm) / (maximal cpm  basal cpm) 9 100.
Maximal 51Cr release was determined by adding Triton X-
100 (1% final concentration) to target cells, and basal
release was measured in the absence of sensitizing antibody
constructs and cd T cells. Unless otherwise indicated,
experiments were performed in the presence of 50 U/ml
IL-2 employing cd T cells as effector cells at an effector-to-
target (E:T) cell ratio of 100:1. cd T cell lines were used
10–12 days after initial stimulation. In selected experi-
ments, BrHPP (Innate Pharma) was added to a final
concentration of 300 nM.
Data processing and statistical analyses. Graphical and
statistical analyses were performed using GraphPad Prism
5.0 software (GraphPad Software, Inc., La Jolla, CA, USA).
P-values were calculated using the student’s t-test or
repeated measures ANOVA and Bonferroni post-test when
appropriate. The null hypothesis was rejected for P < 0.05.
Results
Characterization of CD20-directed immunoligands MICA:7D8
and ULBP2:7D8
To evaluate NKG2D as a trigger molecule on cd T cells,
two recombinant immunoligands consisting of the human
CD20 scFv 7D8 fused to a NKG2D-specific ligand, either
MICA or ULBP2 (Fig. 1A, Figure S1A), were employed,
which had been recently generated to recruit NK cells
against lymphoma or leukaemia cells [35]. Biochemical
characterization indicated that MICA:7D8 and
ULBP2:7D8 were glycosylated proteins of approx. 90–
110 and 55–65 kDa, respectively (Fig. 1B, C), which
behaved as monomers in solution (Figure S1B). Both
immunoligands specifically bound to CD20-positive
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lymphoma cells, and binding was partially blocked by a
recombinant Fab fragment derived from the parental
antibody 7D8 (Figure S1C). Analysis of apparent affinities
to CD20 indicated that the scFv 7D8-moiety contained in
both fusion proteins had similar affinities, regardless
whether it was fusesd to MICA or ULBP2 (Figure S1D).
Calculated KD-values were 1.6  0.1 9 107 M and
1.9  0.1 9 107 M for MICA:7D8 and ULBP2:7D8,
Figure 1 Characteristics of MICA:7D8 and ULBP2:7D8. (A) Ribbon drawing according to homology models of ULBP2:7D8 and MICA:7D8. The
ligands are coloured in green. MICA displays a I–III domains similar to those comprised in the heavy chains of MHC class I molecules, while only a I and
a II domains are contained in ULBP2. VH and VL regions of scFv 7D8 are depicted in red and orange, respectively. Yellow-stained domains indicate the
complementarity determining regions. (B) Integrity of purified MICA:7D8 (lane 1) and ULBP2:7D8 (lane 2) expressed in CHO K1 cells was analysed by
SDS gel electrophoresis under reducing conditions and subsequent staining with coomassie brilliant blue. (C) Purified MICA:7D8 and ULBP2:7D8 were
either deglycosylated under denaturing conditions (+) by applying a mixture of enzymes (O-glycosidase, PNGase F, neuraminidase, b1-4 galactosidase and
b-N-acetylglucosaminidase) or left untreated (), and subsequently analysed by Western blot transfer experiments using an antipenta histidine antibody.
One representative experiment of two performed is shown. (D) Coating of lymphoma cell lines with MICA:7D8 or ULBP2:7D8 increases the surface
density of the corresponding NKG2D-specific ligands. Cells were first coated with MICA:7D8 (upper panel, black peaks) and ULBP2:7D8 (lower panel,
black peaks) or left untreated (grey peaks), and subsequently stained with PE-coupled antibodies specific for MICA/B (upper panel) or ULBP2 (lower panel)
and analysed by flow cytometry. Cellular debris and dead cells were excluded by setting appropriate scatter gates. Endogenous expression of respective
ligands is reflected by the signals obtained with antibodies recognizing the NKG2D ligands in samples with untreated cells (grey peaks). As a control,
untreated cells were incubated with a PE-conjugated control antibody (white peaks). CD20-negative CEM cells served as a control. Note that CEM cells
express considerable amounts of endogenous surface ULBP2. One experiment of two performed is shown.
 2017 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of
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respectively. Finally, we determined the increase in surface-
exposed MICA and ULBP2 that was achieved by coating
the cells with the immunoligands (Fig. 1D). To this end,
the lymphoma cell lines Raji, Ramos and Daudi as well as
the CD20-negative T cell leukaemia cell line CEM were
either pre-incubated with the immunoligands, or left
untreated, and subsequently stained with fluorescence-
conjugated antibodies against MICA/B or ULBP2.
Endogenous cell surface expression of MICA/B and ULBP2
varied between the cell lines, but was moderate or not
detectable. Significantly, pre-incubation with MICA:7D8
and ULBP2:7D8 increased the amounts of MICA and
ULBP2 on the surface of the CD20-positive lymphoma cell
lines by 1–2 orders of magnitude (Fig. 1D).
ULBP2:7D8 and MICA:7D8 enhance cd T cell-mediated lysis of
lymphoma or leukaemia cells
To analyse the ability of MICA:7D8 and ULBP2:7D8 to
enhance cd T cell cytotoxicity, a panel of cd T cell lines
were established from PBMC of healthy donors (Table S1).
The resulting short-term activated or re-stimulated cd T
cell lines, which included both Vd1 or Vd2 cell lines also
strongly expressing NKG2D (Figure S2), were then
analysed as effector cells for MICA:7D8 and ULBP2:7D8.
As a result, both ULBP2:7D8 and MICA:7D8 enhanced
lysis of Raji lymphoma cells significantly in the presence of
Vd2 cd T cells (Fig. 2A). In contrast, no cytotoxic effects
were induced by the immunoligands in the absence of
effector cells, illustrating that cytotoxicity mediated by
both MICA:7D8 and ULBP2:7D8 was effector cell
dependent. Moreover, MICA:7D8 and ULBP2:7D8 did
not mediate killing of CD20-negative cells, as demon-
strated using the CD20-negative plasmacytoma cell line
INA-6 (Fig. 2B). Therefore, both MICA:7D8 and
ULBP2:7D8 triggered cd T cells in a target antigen
restricted manner.
To further study the enhancing effect of MICA:7D8 and
ULBP2:7D8, cytotoxicity experiments were performed
using Raji cells as target cells and Vd2 cd T cells at
varying E:T cell ratios (Fig. 2C). Lysis induced by
MICA:7D8 and ULBP2:7D8 was enhanced with increasing
E:T cell ratios. Similar results were obtained when Vd1 cd
T cells were employed although the extent of lysis was
lower (Fig. 2D). Furthermore, dose-dependent induction of
cytotoxicity was demonstrated for the immunoligands
employing different Vd2 cd T cell lines and Raji or Ramos
lymphoma target cells (Fig. 2E). Both MICA:7D8 and
ULBP2:7D8 were active at nanomolar concentrations. In
experiments with different cd T cell lines, MICA:7D8 had
mean half-maximum effective concentrations (EC50) of
0.04 lg/ml (~0.6 nM) and 0.22 lg/ml (~3.3 nM) for Raji
and Ramos cells, respectively. ULBP2:7D8 had an EC50 of
0.09 lg/ml (~ 1.8 nM) for Raji and an EC50 of 0.3 lg/ml
(~ 6.0 nM) for Ramos cells.
Moreover, cytotoxic effects induced by the immunoli-
gands were demonstrated using various Vd2 or Vd1 cd T
cell lines and different Burkitt lymphoma cell lines
including Raji, Ramos and Daudi (Fig. 3A, B, C, respec-
tively). Whereas none of the cell lines expressed detectable
levels of endogenous MICA, ULBP2 was expressed in
significant amounts by Raji cells and poorly displayed by
Ramos and Daudi (Fig. 1D). Of note, different cd T cell
lines differed in their responses to stimulation with the
immunoligands suggesting that additional parameters may
play an important role, which have not yet been
determined.
Furthermore, the properties of MICA:7D8 and
ULBP2:7D8 to trigger cytotoxicity of cd T cells against
freshly isolated CLL cells were analysed (Fig. 4). Using
different Vd2 cd T cell lines, both MICA:7D8 and
ULBP2:7D8 induced efficient lysis of CLL cells from
different patients, whereas similarly constructed control
molecules were ineffective (Fig. 4A, B). Lysis was induced
in a dose-dependent manner and the immunoligands
triggered cytotoxicity at nanomolar concentrations, similar
to results obtained with lymphoma cell lines (Fig. 4C).
Mean EC50 values were approx. 0.6 lg/ml (~9 nM) and
0.2 lg/ml (~4 nM) for MICA:7D8 and ULBP2:7D8,
respectively.
To provide an additional stimulus for the effector
cells, the immunoligands were analysed in combination
Figure 2 MICA:7D8 and ULBP2:7D8 sensitize lymphoma cells for cd T cell-mediated lysis. (A) MICA:7D8 and ULBP2:7D8 were analysed for the
ability to trigger cd T cells to kill Raji cells in 51Cr release experiments. No cytotoxicity was observed in the absence of cd T cells. The immunoligands
were applied at a concentration of 10 lg/ml. E:T cell ratio was 100:1. Data points represent mean values  SEM from three independent experiments
using different Vd2 T cell lines (*P < 0.05; BR, basal release). (B) ULBP2:7D8 and MICA:7D8 (10 lg/ml) do not trigger cd T cell-mediated killing of
CD20-negative multiple myeloma INA-6 cells (E:T cell ratio: 100:1). The similarly designed immunoligand ULBP2:HM1.24, which targets the CD317
(HM1.24) antigen being expressed by INA-6, was used as a positive control. Data are presented as mean  SEM using different Vd2 T cell lines
(*P < 0.05; BR, basal release; n = 3). (C) Killing of Raji cells by MICA:7D8 (left) and ULBP2:7D8 (right) at varying E:T cell ratios employing Vd2 cd T
cells. Cytotoxicity was analysed in 51Cr release experiments. The immunoligands were applied at a concentration of 10 lg/ml. Data points represent mean
values from six independent experiments (*P < 0.05 relative to the control groups). (D) Killing of Raji cells by MICA:7D8 (left) and ULBP2:7D8 (right)
at varying E:T cell ratios employing Vd1 cd T cells. Data points represent mean values from four independent experiments (*P < 0.05 compared with
control groups). (E) Dose-dependent killing of Raji (left panel) and Ramos cells (right panel) by MICA:7D8 and ULBP2:7D8. Vd2-expressing cd T cell
lines were employed as effector cells at an E:T cell ratio of 100:1. Similarly designed immunoligands containing a scFv against an antigen not expressed by
B-lymphoid tumour cells (contr.-scFv) were used as control. Data points represent mean values  SEM from at least three different experiments with
different cd T cell lines (*P < 0.05 compared with control immunoligand).
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with BrHPP, an agonist for the Vd2Vc9 cd TCR, which
in combination with IL-2 was shown to induce a potent
expansion of cd T lymphocytes in patients with solid
tumours [33]. BrHPP efficiently promoted cytotoxicity of
different Vd2Vc9 cd T cell lines against Raji cells
(Fig. 5A). Interestingly, through the combination of
BrHPP with ULBP2:7D8 or MICA:7D8, lysis of target
cells was further enhanced (Fig. 5A, B). Finally, the
combination of the immunoligands with BrHPP was also
tested with patient-derived CLL cells (Fig. 5C, D).
BrHPP enhanced killing of CLL cells by Vd2 cd T cells
(Fig. 5C), but killing efficacy (~10% lysis in the mean)
remained low in contrast to experiments performed with
Raji cells (~40% Fig. 5A), despite strong surface expres-
sion of CD277 (Figure S3), which plays an important
role in PAg presentation [4, 5]. Impressively, both
MICA:7D8 and ULBP2:7D8 produced significant addi-
tional cytotoxic effects (Fig. 5A, B, C). Thus, the
magnitude of Vd2 cd T cell-mediated lysis of CLL cells
was significantly enhanced by combining the immunoli-
gands with BrHPP, relative to treatment with the single
agents. Again, both MICA:7D8 and ULBP2:7D8 induced
cytotoxicity in a dose-dependent manner (Fig. 5D). In
summary, the two immunoligands MICA:7D8 and
ULBP2:7D8 enhanced the cytotoxic activities of ex vivo-
expanded Vd1 and Vd2 cd T cells resulting in effective
lysis of CD20-positive lymphoma cell lines and patient-
derived CLL cells.
Discussion
In this study, recombinant immunoligands engaging
NKG2D were evaluated for their potential to enhance cd
T cell-mediated cytotoxicity. The human CD20-directed
fusion proteins MICA:7D8 and ULBP2:7D8 were able to
trigger both Vd1 and Vd2 cd T cells and significantly
enhanced their cytotoxicity against lymphoma and leukaemia
cells. These findings demonstrate that biologicals containing
NKG2D-specific ligands may represent an attractive class of
molecules to enhance antitumour responses by cd T cells.
Therapeutic strategies harnessing the antitumoral activ-
ities of NK and cd T cells might be promising approaches
to treat solid tumours and haematologic malignancies [1, 2,
34]. Recombinant immunoligands engaging stimulatory
surface receptors such as NKG2D, NKp30 or NKp80 and
targeting tumour-associated antigens have been shown to
stimulate NK cell cytotoxicity against malignant cells [35,
36, 41–43]. Previously, we have demonstrated that
MICA:7D8 and ULBP2:7D8, which are devoid of the
antibody’s Fc domain and thus are unable to trigger
complement-dependent cytotoxicity or to engage Fc
receptors, triggered NK cells to kill lymphoma or
leukaemia by NKG2D engagement [35]. Moreover, the
fusion proteins synergistically enhanced antibody-depen-
dent cell-mediated cytotoxicity, an important effector
function of therapeutic antibodies [35, 44]. In this study,
we demonstrate that such an approach may be utilized to
trigger T cells, because MICA:7D8 as well as ULBP2:7D8
induced lysis of lymphoma or leukaemia cells by ex vivo-
activated and expanded cd T cells. Thus, apart from NK
cells, cd T cells may represent another potential effector
cell population triggered by MICA:7D8 and ULBP2:7D8.
However, the extent of tumour cell lysis varied between
different cd T cell lines, and it should be noted that with
some lines the immunoligands produced only minor
effects, which may reflect donor variability or differences
in the cd T cell activation status acquired during the
expansion. Noteworthy, the immunoligands enhanced
cytotoxicity by cd T cells even in the presence of BrHPP,
which provided an additional activating stimulus to the
effector cells, suggesting collaboration between the
immunoligands and the phosphorylated antigen. The
additional cytotoxic effects were especially pronounced in
experiments with CLL cells from patients. Our results
indicate that immunoligands selectively targeting cd T
cells to tumour cell-expressed antigens may provide a tool
to further enhance cytotoxic activity of cd T cells where
BrHPP failed due to anergy, exhaustion or depletion of cd
T cells [26, 29, 45, 46].
cd T cells were shown to exert antitumour activities by
directly killing malignant cells and by trans-activating
cells of both the adaptive and the innate immune system
[47, 48]. In particular, cd T cells were shown to enhance
NK cell cytotoxicity either by releasing soluble factors or
through cell–cell contact [49, 50]. Considering that NK
cells activated by cd T cells displayed further increased
NKG2D expression levels and that the observed aug-
mented lytic NK cell activity was found to be at least in
part NKG2D dependent, we anticipate that recruitment of
both NK and cd T cells by NKG2D-directed antibody
derivatives may induce positive feedback loops [49].
Similar to results obtained with NK cells [35],
MICA:7D8 and ULBP2:7D8 were active in the nanomolar
concentration range when cd T cells were employed as
effector cells. There was a trend towards higher activity of
ULBP2:7D8 compared to MICA:7D8, although the
differences between the two immunoligands with cd T
cell effector cells were not as clear as with NK cells [35].
Notably, in the case of cd T cells, also a differential
recognition of the two NKG2D ligands by different TCR
has to be considered. While the Vd1 cd TCR was reported
to recognize MICA, an interaction with ULBP2 has not
been observed [12, 16]. In contrast, Vd2-expressing cd
TCRs usually bind neither ULBP2 nor MICA.
Apart from NK cells and cd T cells, NKG2D is also
expressed by conventional CD8-positive ab T cells and
some CD4-positive ab T cells. However, NKG2D is
believed to have coactivating rather than stimulatory
functions on ab T cells. Whether ab T cells are also
triggered by NKG2D-specific immunoligands has not
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been addressed in detail yet. Activation of polyclonal T
cells has not been observed after exposure to B-lymphoid
tumour cells coated with the immunoligands MICA:7D8
or ULBP2:7D8 [35]. However, it has not been investigated
whether MICA:7D8 and ULBP2:7D8 may selectively
activate certain distinct ab T cell subsets such as effector
memory T cells, or if the induction of cytotoxicity by
polyclonal ab T cells via NKG2D signalling might occur
Figure 3 Efficacy of MICA:7D8 and ULBP2:7D8 with different Vd1 or
Vd2 cd T cell lines. The cytotoxic activity of the immunoligands was
analysed with different Vd1 (open squares) or Vd2 cd T cell lines (filled
black squares) employing Raji (A), Ramos (B) and Daudi lymphoma cells
(C). Data points represent mean values from triplicate determinations.
Similarly, designed immunoligands containing a scFv against an antigen
not expressed by B-lymphoid tumour cells (contr.-scFv) were used as
control. The immunoligands were employed at a concentration of 10 lg/
ml (BR, basal release; *P < 0.05).
Figure 4 MICA:7D8 and ULBP2:7D8 trigger cd T cell-mediated killing
of freshly isolated tumour cells. (A) The cytotoxic activity of the
immunoligands against freshly isolated CLL cells was analysed employing
Vd2 cd T cell lines in a 51Cr release assay. The immunoligands were
employed at a concentration of 10 lg/ml. Similarly, constructed
immunoligands directed against an antigen not expressed by B-
lymphoid tumour cells (contr.-scFv) were used as control. Data points
represent mean values from triplicate determinations, error bars indicate
SEM. Note that different Vd2 cd T cell lines were used in experiments
with different target cells. CLL cell samples from four different patients
were employed. The E:T cell ratio was 100:1 (BR, basal release; p,
patient). (B) For statistical analysis, CLL samples were analysed as a group
(*P < 0.05; n = 4). (C) MICA:7D8 and ULBP2:7D8 triggered cd T cell-
mediated killing of CLL cells (CLL p#1) in a dose-dependent manner at
nanomolar concentrations. Data points represent mean values from three
different experiments using different Vd2 cd T cell lines. Statistical
significant differences in the extent of lysis achieved by either MICA:7D8
and ULBP2:7D8 or the corresponding control constructs are indicated
(*P < 0.05).
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under certain circumstances. For instance, upon stimula-
tion with IL-15 CD8-positive ab T cells have been
demonstrated to kill target cells in a TCR-independent but
NKG2D-dependent manner [51].
In summary, bothMICA:7D8 andULBP2:7D8 enhanced
cytotoxicity by various cd T cell lines indicating that in
addition to NK cells also cdT cells may constitute a relevant
effector cell population for tumour-directed, NKG2D-
specific immunoligands. Thus, employing immunoligands
such as ULBP2:7D8 or MICA:7D for NKG2D engagement
may represent an innovative immunotherapeutic strategy,
which may deserve further evaluation.
Figure 5 Enhanced Vd2 cd T cell-mediated cytotoxicity by combining the immunoligands with BrHPP. (A) Killing of Raji cells by MICA and
ULBP2:7D8 was analysed either in the presence or in the absence of BrHPP. Data points indicate mean values  SEM of four independent experiments.
BrHPP significantly enhanced the magnitude of target cell lysis induced by ULBP2:7D8 (*P < 0.05) or MICA:7D8 (#P < 0.05). The immunoligands
were used at a concentration of 10 lg/ml, and BrHPP at 300 nM. (B) Dose-dependent lysis of Raji cells by ULBP2:7D8 either in the presence or in the
absence of BrHPP. Data points represent mean values  SEM from triplicate determinations. (C) Extent of Vd2 cd T cell-mediated lysis of CLL cells
induced by the immunoligands either in the presence or in the absence of BrHPP. Data points indicate mean values  SEM of three independent
experiments. BrHPP significantly enhanced the magnitude of target cell lysis induced by ULBP2:7D8 (*P < 0.05) or MICA:7D8 (#P < 0.05). (D) Dose-
dependent induction of Vd2 cd T cell cytotoxicity against CLL cells (CLL p#1) by MICA:7D8 and ULBP2:7D8 in the presence of BrHPP (concentration:
300 nM). The E:T cell ratio was 100:1. Data points represent mean values  SEM of three independent experiments (*P < 0.05).
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